Literature DB >> 3203703

Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.

Y F Cheng1, T Lundberg, U Bondesson, L Lindström, J Gabrielsson.   

Abstract

The clinical pharmacokinetics of clozapine, an atypical neuroleptic, was evaluated in 10 chronic schizophrenic male patients after intravenous and oral administration. The mean equilibrium-state concentration ratio between blood and plasma was experimentally determined to be 0.87. The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively. Plasma concentration peaked on average at 3 h. The mean volume of distribution at steady-state and the terminal half-life was 1.6 l/kg and 10.3 h, respectively. A large fraction of the dose is most probably metabolized by some extrahepatic presystemic routes. The large inter-individual variability in the bioavailability and clearance is probably the main reason for large variation in the steady-state plasma level in patients receiving the same oral dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203703     DOI: 10.1007/bf01046700

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Neuroleptic action of clozapine injected into various brain areas in rats.

Authors:  R Fog
Journal:  Int Pharmacopsychiatry       Date:  1975

Review 2.  Effects of neuroleptics on striatal dopamine synthesized from 14C-tyrosine.

Authors:  H Nyback; G Sedvall
Journal:  Pharmacol Ther B       Date:  1976

3.  Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET).

Authors:  P Hartvig; S A Eckernäs; L Lindström; B Ekblom; U Bondesson; H Lundqvist; C Halldin; K Någren; B Långström
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Multiple-dose pharmacokinetics of clozapine in patients.

Authors:  M G Choc; R G Lehr; F Hsuan; G Honigfeld; H T Smith; R Borison; J Volavka
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

5.  Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial.

Authors:  C A León
Journal:  Acta Psychiatr Scand       Date:  1979-05       Impact factor: 6.392

6.  Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.

Authors:  J Gerlach; P Koppelhus; E Helweg; A Monrad
Journal:  Acta Psychiatr Scand       Date:  1974       Impact factor: 6.392

7.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

8.  Effects of clozapine on cerebral catecholaminergic neurone systems.

Authors:  G Bartholini; W Haefely; M Jalfre; H H Keller; A Pletscher
Journal:  Br J Pharmacol       Date:  1972-12       Impact factor: 8.739

9.  Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties.

Authors:  B Ekblom; J E Haggstrom
Journal:  Curr Ther Res Clin Exp       Date:  1974-09

10.  Clozapine-induced agranulocytosis: a situation report up to August 1976.

Authors:  B Anderman; R W Griffith
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  19 in total

1.  In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.

Authors:  Ragy R Girgis; Xiaoyan Xu; Nobumi Miyake; Balu Easwaramoorthy; Roger N Gunn; Eugenii A Rabiner; Anissa Abi-Dargham; Mark Slifstein
Journal:  Neuropsychopharmacology       Date:  2010-12-22       Impact factor: 7.853

2.  Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.

Authors:  Eric Olsson; Gunnar Edman; Leif Bertilsson; Dzana Sudic Hukic; Catharina Lavebratt; Sven V Eriksson; Urban Ösby
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-19

Review 3.  Will routine therapeutic drug monitoring have a place in clozapine therapy?

Authors:  D J Freeman; L K Oyewumi
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 4.  Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.

Authors:  Antona Wagstaff; Caroline Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.

Authors:  José L Moreno; Terrell Holloway; Adrienne Umali; Vinayak Rayannavar; Stuart C Sealfon; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2012-07-28       Impact factor: 4.530

Review 6.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 7.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

8.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 9.  Pharmacokinetics and pharmacodynamics of clozapine.

Authors:  M W Jann; S R Grimsley; E C Gray; W H Chang
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.